265 related articles for article (PubMed ID: 24646283)
1. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.
Hölscher C
Biochem Soc Trans; 2014 Apr; 42(2):593-9. PubMed ID: 24646283
[TBL] [Abstract][Full Text] [Related]
2. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
Hölscher C
Sheng Li Xue Bao; 2014 Oct; 66(5):497-510. PubMed ID: 25331995
[TBL] [Abstract][Full Text] [Related]
3. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
Nowell J; Blunt E; Gupta D; Edison P
Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
[TBL] [Abstract][Full Text] [Related]
4. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
Hölscher C
Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
[TBL] [Abstract][Full Text] [Related]
6. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
Hölscher C
Neuropharmacology; 2018 Jul; 136(Pt B):251-259. PubMed ID: 29402504
[TBL] [Abstract][Full Text] [Related]
7. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease.
Duffy AM; Hölscher C
Neuroscience; 2013 Jan; 228():294-300. PubMed ID: 23103794
[TBL] [Abstract][Full Text] [Related]
8. Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease.
Nowell J; Blunt E; Edison P
Mol Psychiatry; 2023 Jan; 28(1):217-229. PubMed ID: 36258018
[TBL] [Abstract][Full Text] [Related]
9. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
Hölscher C
J Endocrinol; 2014 Apr; 221(1):T31-41. PubMed ID: 23999914
[TBL] [Abstract][Full Text] [Related]
10. Brain insulin resistance: role in neurodegenerative disease and potential for targeting.
Hölscher C
Expert Opin Investig Drugs; 2020 Apr; 29(4):333-348. PubMed ID: 32175781
[No Abstract] [Full Text] [Related]
11. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?
Hölscher C; Li L
Neurobiol Aging; 2010 Sep; 31(9):1495-502. PubMed ID: 18930564
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases.
Batista AF; Bodart-Santos V; De Felice FG; Ferreira ST
CNS Drugs; 2019 Mar; 33(3):209-223. PubMed ID: 30511349
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
Kopp KO; Glotfelty EJ; Li Y; Greig NH
Pharmacol Res; 2022 Dec; 186():106550. PubMed ID: 36372278
[TBL] [Abstract][Full Text] [Related]
14. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models.
Zhang ZQ; Hölscher C
Peptides; 2020 Mar; 125():170184. PubMed ID: 31705913
[TBL] [Abstract][Full Text] [Related]
15. Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells.
Jalewa J; Sharma MK; Hölscher C
J Neurochem; 2016 Oct; 139(1):55-67. PubMed ID: 27412483
[TBL] [Abstract][Full Text] [Related]
16. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
Bak AM; Egefjord L; Gejl M; Steffensen C; Stecher CW; Smidt K; Brock B; Rungby J
Expert Opin Ther Targets; 2011 Oct; 15(10):1153-62. PubMed ID: 21749267
[TBL] [Abstract][Full Text] [Related]
17. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.
Salameh TS; Rhea EM; Talbot K; Banks WA
Biochem Pharmacol; 2020 Oct; 180():114187. PubMed ID: 32755557
[TBL] [Abstract][Full Text] [Related]
18. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?
Bassil F; Fernagut PO; Bezard E; Meissner WG
Prog Neurobiol; 2014 Jul; 118():1-18. PubMed ID: 24582776
[TBL] [Abstract][Full Text] [Related]
19. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.
Calsolaro V; Edison P
CNS Drugs; 2015 Dec; 29(12):1023-39. PubMed ID: 26666230
[TBL] [Abstract][Full Text] [Related]
20. The role of GLP-1 in neuronal activity and neurodegeneration.
Hölscher C
Vitam Horm; 2010; 84():331-54. PubMed ID: 21094907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
